Jun 2026 (Q2 FY26) — Aug 11, 2026
Intensity Therapeutics Q2 FY26 — Clinical Programs Advancing Amidst Funding Efforts
Read the full callIntensity Therapeutics (INTS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Intensity Therapeutics earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -3.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.38 −1.17% · −$0.04
Performance −52.3% 1Y
1Y: $7.08 on 14 Oct 2025 → $3.38. High $33 (30 Oct 2025), low $3.21 (1 Oct 2026).
- Previous close
- $3.42
- 52-week range
- $3.21 – $33
- One year
- −51.23%
Overview
- Symbol
- INTS
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Intensity Therapeutics earnings calls (INTS)
Financials
What the filings say
Net profit, year on year: −19% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -4 | -3 | -3 | -3 | -3 | -3 | -3 | -3 |
| Interest | 0 | 0 | — | — | — | — | — | — |
| Net profit | -4 | -3 | -3 | -3 | -3 | -3 | -2 | -3 |
| EPS ($ per share) | -0.25 | — | -5.51 | -3.36 | -0.06 | — | -0.96 | -1.11 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 |
| Reserves | -39 | -51 | -67 | -78 |
| Total liabilities | 7 | 4 | 2 | 2 |
| Total assets | 2 | 17 | 5 | 14 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -5 | -7 | -15 | -9 |
| Cash from investing | 0 | -6 | 6 | 0 |
| Cash from financing | 2 | 20 | 3 | 19 |
| Net cash flow | -3 | 7 | -6 | 9 |
Insider filings
5 filings between Dec 31, 2025 and Jun 30, 2026.
Open market
decisions to buy or sellNobody bought or sold INTS on the open market in this window. The filings below are 5 awards.
Compensation
not trading decisions- 5
- Award — granted as compensation
Latest filings (7)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Talamo Joseph Chief Financial Officer | Award | 1,093 | $3.8K |
| Jun 30, 2026 | Wesolowski John M Principal Accounting Officer | Award | 3,688 | $12.9K |
| Mar 26, 2026 | BENDER LEWIS H President and CEO | Award | 37,749 | $230.6K |
| Dec 31, 2025 | Talamo Joseph Chief Financial Officer | Award | 14,482 | $3.8K |
| Dec 31, 2025 | Wesolowski John M Principal Accounting Officer | Award | 8,918 | $2.3K |
| Jun 30, 2025 | Talamo Joseph Chief Financial Officer | Award | 14,179 | $3.7K |
| Jun 30, 2025 | Wesolowski John M Principal Accounting Officer | Award | 69,745 | $18.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for INTENSITY THERAPEUTICS, INC.
Free account. Everything above stays public.
Write why you follow INTENSITY THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading